2024
DOI: 10.1038/s41467-024-47587-9
|View full text |Cite
|
Sign up to set email alerts
|

Omecamtiv mecarbil and Mavacamten target the same myosin pocket despite opposite effects in heart contraction

Daniel Auguin,
Julien Robert-Paganin,
Stéphane Réty
et al.

Abstract: Inherited cardiomyopathies are common cardiac diseases worldwide, leading in the late stage to heart failure and death. The most promising treatments against these diseases are small molecules directly modulating the force produced by β-cardiac myosin, the molecular motor driving heart contraction. Omecamtiv mecarbil and Mavacamten are two such molecules that completed phase 3 clinical trials, and the inhibitor Mavacamten is now approved by the FDA. In contrast to Mavacamten, Omecamtiv mecarbil acts as an acti… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
0
0

Year Published

2024
2024
2024
2024

Publication Types

Select...
4
1

Relationship

0
5

Authors

Journals

citations
Cited by 8 publications
references
References 71 publications
0
0
0
Order By: Relevance